FDA grants US Orphan Drug Designation to Medannex's MDX-124

Medannex Ltd (Edinburgh) announced today that its novel therapy, MDX-124, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA).

MDX-124, a first-in-class agent, is currently being studied in humans for the first time, in a Phase 1b clinical trial (the ATTAINMENT trial) in UK patients with advanced cancer.

Driven by compelling non-clinical data, the FDA designation qualifies Medannex for regulatory incentives including tax credits and fee exemptions, as well as the potential for seven years of market exclusivity post-approval in the USA.

MDX-124 is the first therapeutic agent to target annexin-A1, an important modulator of the immune system in health and disease. Targeting annexin-A1 potentially offers significant clinical benefit in the treatment of many cancers - including triple-negative breast, colorectal and lung - as well as autoimmune diseases such as multiple sclerosis, lupus and rheumatoid arthritis. The Orphan Drug Designation has been granted for the treatment of pancreatic cancer, which is the third most common cause of cancer-related death in the USA (American Cancer Society, 2022) and therefore represents a significant unmet clinical need.

Earlier this year, MDX-124 was awarded Orphan Medicinal Product positive opinion from the European Medicines Agency (EMA) as well as an Innovation Passport as part of the Innovative Licencing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Medannex CEO Ian Abercrombie said: ‘This is another significant milestone in the evolution of Medannex and MDX-124. We are delighted to receive such an endorsement from the FDA based on a very strong non-clinical package. This will strengthen our position in the world’s largest healthcare market and we look forward to commencing our clinical programme within the USA’.


More news and updates 

Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion

Grey Wolf Therapeutics closes oversubscribed $50 million Series B Financing Expansion, led by ICG Life Sciences, to accelerate and expand first-of-its-kind antigen modulation technology. This brings the total Series B funds raised to nearly $100 million.

Somnus Scientific announces partnership with Life Science Group and Creonate

Somnus Scientific has agreed a collaborative partnership with Life Science Group (LSG) and Creonate Manufacturing for the next phase of product development.

Coulter Partners DEI: Views from leadership series - Ankit Mahadevia

In the latest instalment of its Diversity, Equity & Inclusion Leadership series, Coulter Partners spoke to Ankit Mahadevia, MD, Founder and Chair of Spero Therapeutics, and author of 'Quiet Leader, Loud Results'.

Discovery Park: Asymchem secures former Pfizer Sandwich, UK, development

Asymchem will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe.

Ultra-concentrated, ultra-rapid acting insulin demonstrates superiority in Phase I clinical trial in Type 2 diabetics

AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI

DLRC achieves King’s Award for Enterprise in International Trade

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

Brainomix achieves breakthrough with FDA clearance of e-Lung AI software

Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space; with this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging biomarkers.

Brainomix announces new studies further validating the impact of Brainomix 360 Stroke platform

With these latest studies, the firmly established European market leader in stroke AI imaging adds to its growing body of evidence; the latest research reflects the company’s extensive academic collaborations and its growing Life Science partnerships.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

New study shows Brainomix 360 AI transforms stroke treatment in England

The study represents the largest real-world evaluation of stroke artificial intelligence (AI) imaging, involving more than 80,000 patients at 26 sites over a 3-year period; the results showed Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, while also improving the speed of treatment by 49 minutes.


More within